Table Info

Table 1.

mRNA drugs used for prevention and treatment of diseases

Disease type	Name	Administration route
Infectious diseases
COVID-19	NT162b2	i.m.
COVID-19	mRNA-1273
Rabies	RVG-SAM	i.m.
Cancer
A20-OVA lymphoma	OVA mRNA	i.v.
B16F10-OVA melanoma	OVA mRNA	i.v.
Hepa1-6 orthotopic HCC tumor	BisCCL2/5i mRNA	i.v.
Cardiovascular diseases
Familial hypercholesterolaemia and atherosclerotic cardiovascular diseases	mRNA encoding Cas9	i.v.
Type 2 diabetes	VEGF-A mRNA	i.d.
Genetic disorder
Monogenic retinal degenerative disorders of retinal pigmented epithelium	EGFP mRNA	Subretinal injection
Methylmalonic acidemia	mRNA encoding human wild-type MCMUT	i.v.
Fabry disease	α-Gal A mRNA	i.v.

CCL2: C-C motif chemokine ligand 2; EGFP: enhanced green fluorescence protein; HCC: hepatocellular carcinoma; MCMUT: methylmalonyl-coenzyme A (CoA)-mutase; RVG-SAM: self-amplifying RNA encoding the rabies virus glycoprotein; VEGF-A: vascular endothelial growth factor A; α-Gal A: alpha-galactosidase A

Declarations

Author contributions

The manuscript was written by HF; HF and QC revised the original manuscript. All authors have given approval to the final version of the manuscript.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was financially supported by the China Postdoctoral Science Foundation (2020M681708), Jiangsu Postdoctoral Research Finding Program (2021K355C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359:eaan4672. [DOI] [PubMed]

Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–60. [DOI] [PubMed]

Fang H, Guo Z, Chen J, Lin L, Hu Y, Li Y, et al. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat Commun. 2021;12:6742. [DOI] [PubMed] [PMC]

Brenner S, Jacob F, Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature. 1961;190:576–81. [DOI] [PubMed]

Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. 1989;86:6077–81. [DOI] [PubMed] [PMC]

Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–8. [DOI] [PubMed]

May M. After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases. Nat Med. 2021;27:930–2. [DOI] [PubMed]

Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A. 2018;115:E9153–61. [DOI] [PubMed] [PMC]

Yan Y, Xiong H, Zhang X, Cheng Q, Siegwart DJ. Systemic mRNA delivery to the lungs by functional polyester-based carriers. Biomacromolecules. 2017;18:4307–15. [DOI] [PubMed]

10.

Dilliard SA, Siegwart DJ. Disrupting off-target Cas9 activity in the liver. Nat Biomed Eng. 2022;6:106–7. [DOI] [PubMed]

11.

Zhang D, Wang G, Yu X, Wei T, Farbiak L, Johnson LT, et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17:777–87. [DOI] [PubMed]

12.

Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15:313–20. [DOI] [PubMed] [PMC]

13.

Liu S, Cheng Q, Wei T, Yu X, Johnson LT, Farbiak L, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater. 2021;20:701–10. [DOI] [PubMed] [PMC]

14.

Chiper M, Tounsi N, Kole R, Kichler A, Zuber G. Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. J Control Release. 2017;246:60–70. [DOI] [PubMed]

15.

Fang H, Chen J, Lin L, Liu F, Tian H, Chen X. A strategy of killing three birds with one stone for cancer therapy through regulating the tumor microenvironment by H₂O₂-responsive gene delivery system. ACS Appl Mater Interfaces. 2019;11:47785–97. [DOI] [PubMed]

16.

Fang H, Feng Y, Chen J, Tian H, Chen X. Constructing efficient polycationic gene carriers through regulating the physicochemical properties. Mater Today Chem. 2019;11:269–82. [DOI]

17.

Fang H, Lin L, Chen J, Wu J, Tian H, Chen X. Zinc ion coordination significantly improved the transfection efficiency of low molecular weight polyethylenimine. Biomater Sci. 2019;7:1716–28. [DOI] [PubMed]

18.

Fang H, Guo Z, Lin L, Chen J, Sun P, Wu J, et al. Molecular strings significantly improved the gene transfection efficiency of polycations. J Am Chem Soc. 2018;140:11992–2000. [DOI] [PubMed]

19.

Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184:1589–603. [DOI] [PubMed] [PMC]

20.

Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83–112. [DOI] [PubMed] [PMC]

21.

Zhao W, Hou X, Vick OG, Dong Y. RNA delivery biomaterials for the treatment of genetic and rare diseases. Biomaterials. 2019;217:119291. [DOI] [PubMed] [PMC]

22.

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79. [DOI] [PubMed] [PMC]

23.

Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–28. [DOI] [PubMed] [PMC]

24.

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–80. [DOI] [PubMed]

25.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078–94. [DOI] [PubMed] [PMC]

26.

Grau M, Walker PR, Derouazi M. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. Cell Mol Life Sci. 2018;75:2887–96. [DOI] [PubMed] [PMC]

27.

Qiu Y, Man RCH, Liao Q, Kung KLK, Chow MYT, Lam JKW. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102–15. [DOI] [PubMed]

28.

Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30:1210–6. [DOI] [PubMed]

29.

McKinlay CJ, Vargas JR, Blake TR, Hardy JW, Kanada M, Contag CH, et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A. 2017;114:E448–56. [DOI] [PubMed] [PMC]

30.

Jarzębińska A, Pasewald T, Lambrecht J, Mykhaylyk Ö, Kümmerling L, Beck P, et al. A single methylene group in oligoalkylamine-based cationic polymers and lipids promotes enhanced mRNA delivery. Angew Chem Int Ed Engl. 2016;55:9591–5. [DOI] [PubMed]

31.

Uchida H, Itaka K, Nomoto T, Ishii T, Suma T, Ikegami M, et al. Modulated protonation of side chain aminoethylene repeats in N-substituted polyaspartamides promotes mRNA transfection. J Am Chem Soc. 2014;136:12396–405. [DOI] [PubMed]

32.

Cheng C, Convertine AJ, Stayton PS, Bryers JD. Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials. 2012;33:6868–76. [DOI] [PubMed] [PMC]

33.

Erasmus JH, Khandhar AP, Walls AC, Hemann EA, O’Connor MA, Murapa P, et al. Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates. bioRxiv:10.1101/2020.05.28.121640 [Preprint]. 2020 [cited 2020 May 28]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.28.121640v1 [DOI] [PubMed] [PMC]

34.

Erasmus JH, Khandhar AP, O’Connor MA, Walls AC, Hemann EA, Murapa P. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med. 2020;12:eabc9396. [DOI] [PubMed] [PMC]

35.

O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59^® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12:13–30. [DOI] [PubMed]

36.

Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis. 2015;211:947–55. [DOI] [PubMed] [PMC]

37.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. [DOI] [PubMed] [PMC]

38.

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al.; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38. [DOI]

39.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. [DOI] [PubMed] [PMC]

40.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401. [DOI] [PubMed]

41.

Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013;21:358–67. [DOI] [PubMed] [PMC]

42.

Lei S, Zhang X, Men K, Gao Y, Yang X, Wu S, et al. Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation. Mol Pharm. 2020;17:3378–91. [DOI] [PubMed]

43.

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31:638–46. [DOI] [PubMed]

44.

Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2017;2:17056. [DOI]

45.

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. [DOI] [PubMed]

46.

Nabhan JF, Wood KM, Rao VP, Morin J, Bhamidipaty S, LaBranche TP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci Rep. 2016;6:20019. [DOI] [PubMed] [PMC]

47.

Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the sprague-dawley rat and cynomolgus monkey. Vet Pathol. 2018;55:341–54. [DOI] [PubMed]

48.

Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22:2227–35. [DOI] [PubMed]

49.

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega JB, Karmali PP, et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017;114:E1941–50. [DOI] [PubMed] [PMC]

50.

An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21:3548–58. Erratum in: Cell Rep. 2018;24:2520. [DOI] [PubMed]

51.

Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26:1509–19. [DOI] [PubMed] [PMC]

52.

Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15:7300–6. [DOI] [PubMed]

53.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17:1326–35. [DOI] [PubMed] [PMC]

54.

Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34:328–33. [DOI] [PubMed] [PMC]

55.

Meng C, Chen Z, Li G, Welte T, Shen H. Nanoplatforms for mRNA therapeutics. Adv Ther. 2020;4:2000099. [DOI]

56.

Koltover I, Salditt T, Rädler JO, Safinya CR. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science. 1998;281:78–81. [DOI] [PubMed]

57.

Ryals RC, Patel S, Acosta C, McKinney M, Pennesi ME, Sahay G. The effects of PEGylation on LNP based mRNA delivery to the eye. PLoS One. 2020;15:e0241006. [DOI] [PubMed] [PMC]

58.

Zhu X, Tao W, Liu D, Wu J, Guo Z, Ji X, et al. Surface De-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo. Theranostics. 2017;7:1990–2002. [DOI] [PubMed] [PMC]

59.

Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther. 2009;17:872–9. [DOI] [PubMed] [PMC]

60.

Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49:6288–308. [DOI] [PubMed]

61.

Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020;20:4543–9. [DOI] [PubMed] [PMC]

62.

Paunovska K, Da Silva Sanchez AJ, Sago CD, Gan Z, Lokugamage MP, Islam FZ, et al. Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses. Adv Mater. 2019;31:1807748. [DOI] [PubMed] [PMC]

63.

Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406–24. [DOI] [PubMed]

64.

Feiner-Gracia N, Olea RA, Fitzner R, El Boujnouni N, van Asbeck AH, Brock R, et al. Super-resolution imaging of structure, molecular composition, and stability of single oligonucleotide polyplexes. Nano Lett. 2019;19:2784–92. [DOI] [PubMed] [PMC]

65.

Coolen AL, Lacroix C, Mercier-Gouy P, Delaune E, Monge C, Exposito JY, et al. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials. 2019;195:23–37. [DOI] [PubMed]

66.

Lou B, De Koker S, Lau CYJ, Hennink WE, Mastrobattista E. mRNA polyplexes with post-conjugated GALA peptides efficiently target, transfect, and activate antigen presenting cells. Bioconjug Chem. 2019;30:461–75. [DOI] [PubMed] [PMC]

67.

Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv. 2016;23:2596–607. [DOI] [PubMed]

68.

Blakney AK, Abdouni Y, Yilmaz G, Liu R, McKay PF, Bouton CR, et al. Mannosylated poly(ethylene imine) copolymers enhance saRNA uptake and expression in human skin explants. Biomacromolecules. 2020;21:2482–92. [DOI] [PubMed]

69.

Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26:446–55. [DOI] [PubMed] [PMC]

70.

Liu S, Wang X, Yu X, Cheng Q, Johnson LT, Chatterjee S, et al. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J Am Chem Soc. 2021;143:21321–30. [DOI] [PubMed]

71.

Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49–56. [DOI] [PubMed]

72.

Tateshita N, Miura N, Tanaka H, Masuda T, Ohtsuki S, Tange K, et al. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. J Control Release. 2019;310:36–46. [DOI] [PubMed]

73.

Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 2015;14:161–76. [DOI] [PubMed]

74.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22:2118–29. [DOI] [PubMed] [PMC]

75.

Melo M, Porter E, Zhang Y, Silva M, Li N, Dobosh B, et al. Immunogenicity of RNA replicons encoding HIV Env immunogens designed for self-assembly into nanoparticles. Mol Ther. 2019;27:2080–90. [DOI] [PubMed] [PMC]

76.

Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–51. [DOI] [PubMed] [PMC]

77.

Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015;203:1–15. [DOI] [PubMed]

78.

Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12:967–77. [DOI] [PubMed]

79.

Dong Y, Love KT, Dorkin JR, Sirirungruang S, Zhang Y, Chen D, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A. 2014;111:3955–60. Erratum in: Proc Natl Acad Sci U S A. 2014;111:5753. [DOI] [PMC]

80.

Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021;12:613. Erratum in: Nat Commun. 2021;12:2825. [DOI] [PubMed] [PMC]

81.

Asai T, Oku N. Systemic delivery of small RNA using lipid nanoparticles. Biol Pharm Bull. 2014;37:201–5. [DOI] [PubMed]

82.

Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol Ther. 2019;27:1415–23. [DOI] [PubMed] [PMC]

83.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23:815–7. Erratum in: Nat Med. 2017;23:1241. [DOI] [PubMed]

84.

Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630. [DOI] [PubMed] [PMC]

85.

Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, et al. Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol Ther Nucleic Acids. 2016;5:E326. [DOI] [PubMed] [PMC]

86.

Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31:898–907. [DOI] [PubMed] [PMC]

87.

Friedmann T. An ASGCT perspective on the national academies genome editing summit. Mol Ther. 2016;24:1–2. [DOI] [PubMed] [PMC]

88.

Patel S, Ryals RC, Weller KK, Pennesi ME, Sahay G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J Control Release. 2019;303:91–100. [DOI] [PubMed] [PMC]

89.

Devoldere J, Peynshaert K, Dewitte H, Vanhove C, De Groef L, Moons L, et al. Non-viral delivery of chemically modified mRNA to the retina: subretinal versus intravitreal administration. J Control Release. 2019;307:315–30. [DOI] [PubMed]

90.

Anderson DM, Hall LL, Ayyalapu AR, Irion VR, Nantz MH, Hecker JG. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum Gene Ther. 2003;14:191–202. [DOI] [PubMed]

91.

Zeng C, Zhang C, Walker PG, Dong Y. Formulation and delivery technologies for mRNA vaccines. In: Ahmed R, Akira S, Casadevall A, Galan JE, Garcia-Sastre A, Malissen B, et al., editors. Current topics in microbiology and immunology. Berlin: Springer; 2020. pp. 1–40. [DOI]

92.

Feldman RA, Fuhr R, Smolenov I (Mick), Ribeiro A, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326–34. [DOI] [PubMed]

93.

Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25:1316–27. Erratum in: Mol Ther. 2022;30:2874. [DOI] [PubMed] [PMC]

94.

Li Y, Su Z, Zhao W, Zhang X, Momin N, Zhang C, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat Cancer. 2020;1:882–93. [DOI] [PubMed] [PMC]

95.

Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, et al. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 2019;79:1624–34. [DOI] [PubMed] [PMC]

96.

Zhao P, Hou X, Yan J, Du S, Xue Y, Li W, et al. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020;5:358–63. [DOI] [PubMed] [PMC]

97.

Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172:38–47. [DOI] [PubMed]

98.

Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–75. [DOI] [PubMed]

99.

Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521–5. [DOI] [PubMed]

100.

Abrams MT, Koser ML, Seitzer J, Williams SC, DiPietro MA, Wang W, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18:171–80. [DOI] [PubMed] [PMC]

101.

Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–75. [DOI] [PubMed]

102.

Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39:e142. [DOI] [PubMed] [PMC]

103.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25:1663–9. [DOI] [PubMed]

104.

Castanha PMS, Marques ETA. A glimmer of hope: recent updates and future challenges in Zika vaccine development. Viruses. 2020;12:1371. [DOI] [PubMed] [PMC]

105.

Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: the impact of cationic lipid selection. J Control Release. 2020;325:370–9. [DOI] [PubMed]

106.

Fang H, Tian H, Chen X. A pH-sensitive cationic micelle for siRNA delivery. J Controlled Release. 2017;259:e47. [DOI]

107.

Ni W, Wu J, Fang H, Feng Y, Hu Y, Lin L, et al. Photothermal-chemotherapy enhancing tumor immunotherapy by multifunctional metal-organic framework based drug delivery system. Nano Lett. 2021;21:7796–805. [DOI] [PubMed]

108.

Chen J, Fang H, Hu Y, Wu J, Zhang S, Feng Y, et al. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy. Bioact Mater. 2021;7:167–80. [DOI] [PubMed] [PMC]

109.

Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37:1174–85. [DOI] [PubMed]

110.

Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33:2007603. [DOI] [PubMed] [PMC]

111.

Islam MA, Rice J, Reesor E, Zope H, Tao W, Lim M, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431. [DOI] [PubMed] [PMC]

112.

Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12:627–42. [DOI] [PubMed]

113.

Lim GB. Global burden of cardiovascular disease. Nat Rev Cardiol. 2013;10:59. [DOI] [PubMed]

114.

Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743–53. [DOI] [PubMed]

115.

Gan LM, Lagerström-Fermér M, Carlsson LG, Arfvidsson C, Egnell AC, Rudvik A, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat Commun. 2019;10:871. [DOI] [PubMed] [PMC]

116.

Martini PGV, Guey LT. A new era for rare genetic diseases: messenger RNA therapy. Hum Gene Ther. 2019;30:1180–9. [DOI] [PubMed]

117.

Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B, et al. Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104:625–37. [DOI] [PubMed] [PMC]